19:30 , Oct 13, 2017 |  BioCentury  |  Product Development

Eyeing complement data

Clinical studies of four complement inhibitors in patients with age-related macular degeneration suggest the best target in the pathway may be complement 3 . However, differences between study populations and methods and durations of treatment...
23:20 , Jul 11, 2017 |  BioCentury  |  Emerging Company Profile

Complementary ALS play

Alsonex Pty. Ltd. is targeting a central component of the complement cascade to quell neuroinflammation in amyotrophic lateral sclerosis without excessively dampening the immune system. That mechanism could slow disease progression and improve life expectancy...
07:00 , Aug 7, 2014 |  BC Innovations  |  Targets & Mechanisms

Adipsin meets beta cells

The long-standing mystery of how adipsin regulates metabolism has been solved by a Harvard-led team that has shown the enzyme can increase insulin secretion by generating the peptide complement 3a . 1 Its therapeutic potential...
23:44 , Apr 16, 2014 |  BC Extra  |  Financial News

Vital raises $54 million in IPO

Liver disease company Vital Therapies Inc. (NASDAQ:VTL) raised $54 million through the sale of 4.5 million shares at $12 in an IPO underwritten by BofA Merrill Lynch; Credit Suisse; William Blair; and Canaccord. The price...
01:26 , Apr 8, 2014 |  BC Extra  |  Financial News

Vital sets IPO range

Liver disease company Vital Therapies Inc. (San Diego, Calif.) amended its IPO on NASDAQ and now plans to sell 4.5 million shares at $13-$15. At the $14 midpoint, the company would raise $63 million and...
00:42 , Mar 12, 2014 |  BC Extra  |  Financial News

Liver company Vital revives IPO plans

Vital Therapies Inc. (San Diego, Calif.) revitalized plans for an IPO on NASDAQ. The company postponed its IPO in November, citing market conditions. On Tuesday, Vital filed an S-1A that no longer contains a share...
01:24 , Nov 22, 2013 |  BC Extra  |  Financial News

Vital Therapies postpones IPO

Liver company Vital Therapies Inc. (San Diego, Calif.) postponed its IPO due to market conditions, according to a Wall Streeter who asked to remain anonymous. Earlier this month, Vital amended its IPO and said it...
01:36 , Nov 7, 2013 |  BC Extra  |  Financial News

Biocept, Trevena, Vital set IPO ranges

Neurology company Trevena Inc. (King of Prussia, Pa.), liver company Vital Therapies Inc. (San Diego, Calif.) and cancer diagnostic company Biocept Inc. (San Diego, Calif.) amended their IPOs on Wednesday. Trevena plans to sell 5.8...
00:12 , Oct 12, 2013 |  BC Extra  |  Top Story

Four more biotechs join IPO queue

Four more biotechs announced IPO plans on Friday, bringing the queue by BioCentury's tally to at least 21. Gene therapy company Celladon Corp. (San Diego, Calif.) filed to raise up to $86.3 million in an...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Clinical News

ELAD system regulatory update

The European Commission granted Orphan Drug designation for Vital Therapies' human liver cell-based extracorporeal liver assist device (ELAD) to treat acute liver failure. The product is in Phase III testing to treat alcohol-induced liver failure...